In a representative retrospective study, Su et al.84compared 197 patients with HCC who received either triple therapy (PD-1 inhibitors + anti-angiogenic therapy + intensity-modulated radiation therapy [IMRT], n = 54) or dual therapy (PD-1 inhibitors + anti-angiogenic therapy, n = 143). Here, PDCD1 is linked to hepatocellular carcinoma.